Role of Immature Reticulocytes as an Early Indicator of Engraftment in Bone Marrow Transplantation in Thalassemia Major Patients
DOI:
https://doi.org/10.21276/apalm.3829Keywords:
bone marrow transplant, bone marrow engraftment, immature reticulocytes fraction, high fluorescent reticulocyte, absolute neutrophil countAbstract
Background: Absolute neutrophil count (ANC) is the conventional indicator of bone marrow engraftment. Recently, new reticulocyte parameters like Immature Reticulocyte Fraction (IRF) and High Fluorescence Reticulocyte (HFR) have been used as new markers of engraftment. HFR provides a very early and sensitive index of marrow erythropoietin activity. Our aim is to study the role of Immature Reticulocyte parameters as early indicators of engraftment in BMT patients.Methods: In this hospital-based prospective observational study, all allogenic BMT cases of thalassemia major (n=30) were recruited over 18 months period. Complete blood count (CBC) parameters including ANC, Absolute monocyte count (AMC), Absolute reticulocyte count, Reticulocyte%, IRF and HFR were determined from the day before the BMT, the infusion day (day 0), and thereafter on a daily basis until achievement of engraftment (ANC >500/µl).
Results: Out of 30 cases, 26 patients achieved engraftment. The mean day of achievement of ANC>500/ul was 20.77 (median day 20) and IRF>10% was 15.39 ± 4.34 (median day 16). Median day of IRF was achieved 4 days before ANC. Mean day of HFR>3% was 15.25 (Median day 14). Median day of HFR was achieved 6 days before ANC. These correlations were significant (P value<0.001).
Conclusion: Based on these findings, we suggest that serial measurement of IRF >10%, HFR >3% and AMC >100/μl should be routinely used to trace hematopoietic restoration after BMT because these parameters preceded standard neutrophil recovery (ANC >500/μl) which is a traditional marker of engraftment after BMT.
References
1. Colah R, Italia K, Gorakshakar A. Burden of thalassemia in India: The road map for control. Pediatric Hematology Oncology Journal. Dec. 2017, 2:79-84.
2. Khaddour K, Hana CK, Mewawalla P. Hematopoietic Stem Cell Transplantation. 2023 May 6.
3. Lucarelli G, Giardini C, Baronciani D. Bone marrow transplantation in thalassemia. Semin Hematol. 1995 Oct;32(4):297-303.
4. Galambrun C, Pondarré C, Bertrand Y, Loundou A, Bordigoni P, Frange P et al. French Rare Disease Center for Thalassemia; French Society of Bone Marrow Transplantation. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: lessons and future directions. Biol Blood Marrow Transplant. 2013 Jan;19(1):62-8.
5. Tommasi M, d'Onofrio G, Zini G, Salutari P, Sica S, Leone G. Reticulocyte Parameters as Early Indicators of Hematopoietic Recovery after Bone marrow Transplantation. Molecular Biology of Hematopoiesis. 5:83-91.
6. Raanani P, Levi I, Holzman F, Grotto I, Brok-Simoni F, Avigdor A et al. Engraftment-associated hypophosphatemia--the role of cytokine release and steep leukocyte rise post stem cell transplantation. Bone Marrow Transplant. 2001 Feb;27(3):311-7.
7. d'Onofrio G, Tichelli A, Foures C, Theodorsen L. Indicators of haematopoietic recovery after bone marrow transplantation: the role of reticulocyte measurements. Clin Lab Haematol. 1996 Dec;18 Suppl 1:45-53.
8. Molina J, Joaquín Sánchez‐García, Torres A, Álvarez MA, Serrano J, Casaño J, et al. Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 1 Feb. 2007, 13:172-82.
9. Qin F, Shi L, Li Q, Zhang Z, Liu L, Li J et al. Immune recovery after in vivo T-cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta-thalassemia children. Eur J Haematol. 2019 Oct;103(4):342-350.
10. Huang C, Qu Y, Liu S, Nie S, Jiang H. Hematopoietic stem cell transplantation for thalassemia major using HLA fully-matched and mismatched donor grafts. Transl Pediatr. 2021 Jun;10(6):1552-65.
11. Choudhary D, Doval D, Sharma SK, Khandelwal V, Setia R, Handoo A. Allogenic Hematopoietic Cell Transplantation in Thalassemia Major: A Single-center Retrospective Analysis From India. J Pediatr Hematol Oncol. 2019 Jul;41(5):e296-e301.
12. Mustafa M, Qatawneh M, Al Jazazi M, Jarrah O, Al Hazaimeh R, Oudat R et al. Hematopoietic Stem Cell Transplantation in Thalassemia Patients: a Jordanian Single Centre Experience. Mater Sociomed. 2020 Dec;32(4):277-82.
13. Davies SV, Cavill I, Bentley N, Fegan CD, Poynton CH, Whittaker JA. Evaluation of erythropoiesis after bone marrow transplantation: quantitative reticulocyte counting. Br J Haematol. 1992 May;81(1):12-7.
14. Dr. Angel F. Remacha. Flow cytometric reticulocyte quantification in the evaluation of hematologic recovery. Spanish Multicentric Study Group for Hematopoietic Recovery. Eur J Haematol. Nov. 1994, 53(5):293-7.
15. Noronha JF, De Souza CA, Vigorito AC, Aranha FJ, Zulli R, Miranda EC et al. Immature reticulocytes as an early predictor of engraftment in autologous and allogeneic bone marrow transplantation. Clin Lab Haematol. 2003 Feb;25(1):47-54.
16. von Asmuth EGJ, Mohseny AB, Putter H, Schilham MW, Lankester AC. Modeling Long-Term Erythropoietic Recovery After Allogeneic Stem Cell Transplants in Pediatric Patients. Front Pediatr. 2020 Nov 30;8:584156.
17. Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen
18. Cario H. Hemaglobinopathies-genetically diverse, clinically complex, and globally relevant. memo - Magazine of European Medical Oncology. 13 Apr. 2018:235-40.
19. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021 Dec;9(12):e1788.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Amit Kumar Maharia, Arpita Mathur, Priya Marwah, Anjana Mittal, Shweta Bansal, Manoj Sharma, Pooja Rani
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
